Catalent strengthens leadership position in Asia-Pacific
Company announces key appointments and a new sales office in Korea.
Catalent Pharma Solutions has announced two key appointments and the opening of a new sales office in Korea to support the company’s continued investment and strategic growth plans in the Asia Pacific region.
Howard Kim has joined the company in the role of Director of Business Development in Korea, and will work between Catalent’s new sales office in Seoul, South Korea, and the company’s Somerset, NJ, headquarters. Mr Kim will manage business development activities across all of Catalent’s business units in the expanding Korean market.
Prior to joining Catalent, Mr Kim was responsible for developing businesses for Korean pharmaceutical companies in the US and in Europe. He has also worked for Novartis, Sandoz, Schering-Plough, Wyeth, and Merck in the areas of product supply and planning.
In a second appointment, Erin Vlack has been promoted to Manager of the company’s new Clinical Supply Services site in Kakegawa, Japan, which is to provide secondary packaging, labeling, storage and distribution capabilities locally.
In this role, Ms Vlack will establish and lead the site’s clinical supply operations, driving the business strategy, achieving necessary regulatory standards, meeting on-time delivery, quality, and efficiency targets, and establishing safe working practices within the site’s cGMP environment.
Ms Vlack has 12 years of progressive project management experience, a decade of which spans Japanese business strategy, contract manufacturing, pharmaceutical and clinical trial logistics, and supply and depot management. Since joining Catalent in April 2015, Ms Vlack has held the role of Project Manager at the company’s Morrisville, North Carolina facility in the US. Prior to this she lived, studied and worked in and around Japan for over 20 years.
Catalent has offered clinical supply services in the region since 2005, and within the past 3 years has made significant capital investments totaling more than $10 million with additional personnel to expand its overall Asia-Pacific footprint to meet growing customer demand. Today, the company’s network spans nine audited depots and three fully owned and operated clinical packaging facilities in China, Singapore, and Japan when it opens for business later this year. Available services include primary and secondary packaging, demand led supply services, clinical storage, cold chain services, global distribution, comparator sourcing, project management, clinical supply management, regulatory consulting, and returns and destruction.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.